EA201490433A1 - Новое антитело против ngf человека - Google Patents

Новое антитело против ngf человека

Info

Publication number
EA201490433A1
EA201490433A1 EA201490433A EA201490433A EA201490433A1 EA 201490433 A1 EA201490433 A1 EA 201490433A1 EA 201490433 A EA201490433 A EA 201490433A EA 201490433 A EA201490433 A EA 201490433A EA 201490433 A1 EA201490433 A1 EA 201490433A1
Authority
EA
Eurasian Patent Office
Prior art keywords
human ngf
antibody against
antibody
antigen
seq
Prior art date
Application number
EA201490433A
Other languages
English (en)
Other versions
EA024292B1 (ru
Inventor
Масадзуми Камохара
Хироцугу Танака
Юкари Койа
Дзун Такасаки
Ацуо Йонезава
Еидзи Йосими
Original Assignee
Астеллас Фарма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астеллас Фарма Инк. filed Critical Астеллас Фарма Инк.
Publication of EA201490433A1 publication Critical patent/EA201490433A1/ru
Publication of EA024292B1 publication Critical patent/EA024292B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Предлагается получить антитело против NGF человека, которое обладает уменьшенными влиянием на плод и риском побочных действий, включающим тромбоз, при сохранении высокой нейтрализующей активности и которое имеет превосходную безопасность, или его антигенсвязывающий фрагмент; и средство профилактики или лечения различных заболеваний, развитие болезненных состояний которых связано с NGF человека, который использует антитело или его антигенсвязывающий фрагмент. Решение осуществляется за счет фрагмента Fab' антитела против NGF человека, который содержит вариабельный участок тяжелой цепи, содержащий аминокислотную последовательность SEQ ID NO:6, и вариабельный участок легкой цепи, содержащий аминокислотную последовательность SEQ ID NO:4.
EA201490433A 2011-08-11 2012-08-10 Новое антитело против ngf человека EA024292B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2011176209 2011-08-11
JP2011269215 2011-12-08
PCT/JP2012/070433 WO2013022083A1 (ja) 2011-08-11 2012-08-10 新規抗ヒトｎｇｆ抗体

Publications (2)

Publication Number Publication Date
EA201490433A1 true EA201490433A1 (ru) 2014-05-30
EA024292B1 EA024292B1 (ru) 2016-09-30

Family

ID=47668585

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201490433A EA024292B1 (ru) 2011-08-11 2012-08-10 Новое антитело против ngf человека

Country Status (28)

Country Link
US (2) US8986952B2 (ru)
EP (1) EP2743348B1 (ru)
JP (1) JP5376095B2 (ru)
KR (1) KR101999867B1 (ru)
CN (1) CN103748222B (ru)
AR (1) AR087506A1 (ru)
AU (1) AU2012293161B2 (ru)
BR (1) BR112014002576B1 (ru)
CA (1) CA2841181C (ru)
CY (1) CY1119914T1 (ru)
DK (1) DK2743348T3 (ru)
EA (1) EA024292B1 (ru)
ES (1) ES2663968T3 (ru)
HR (1) HRP20180155T1 (ru)
HU (1) HUE036079T2 (ru)
IL (1) IL230797A (ru)
IN (1) IN2014CN00614A (ru)
LT (1) LT2743348T (ru)
ME (1) ME02944B (ru)
MX (1) MX351273B (ru)
NO (1) NO2743348T3 (ru)
PL (1) PL2743348T3 (ru)
PT (1) PT2743348T (ru)
RS (1) RS56876B1 (ru)
SI (1) SI2743348T1 (ru)
TW (1) TWI554519B (ru)
WO (1) WO2013022083A1 (ru)
ZA (1) ZA201400741B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
WO2012075340A2 (en) 2010-12-01 2012-06-07 Alderbio Holdings Llc Anti-ngf compositions and use thereof
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
JP6135161B2 (ja) * 2013-02-08 2017-05-31 アステラス製薬株式会社 新規抗ヒトｎｇｆ抗体
US9127055B2 (en) 2013-02-08 2015-09-08 Astellas Pharma Inc. Method of treating pain with anti-human NGF antibody
CN107614683B (zh) * 2015-05-22 2020-12-22 安斯泰来制药株式会社 新型抗人NGF抗体Fab片段
CA3018473A1 (en) 2016-03-25 2017-09-28 Astellas Pharma Inc. Pharmaceutical composition comprising pegylated fab' fragment of anti-human ngf antibody
CN114751982B (zh) * 2017-12-15 2023-06-23 安源医药科技（上海）有限公司 抗人ngf抗体及其制备方法和用途
EP3795176A4 (en) 2018-05-15 2022-01-12 Astellas Pharma Inc. PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF ATRIAL FIBRILLATION WITH ANTI-HUMAN NGF ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AS AN ACTIVE SUBSTANCE

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101653604A (zh) 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
PT2270048E (pt) 2002-12-24 2016-02-10 Rinat Neuroscience Corp Anticorpos anti-ngf e métodos de utilização dos mesmos
EA013614B1 (ru) 2003-07-15 2010-06-30 Амджен Инк. Изолированное антитело к фактору роста нервов (ngf) и способы его применения
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
CA2595800C (en) 2005-01-24 2014-07-08 Cambridge Antibody Technology Limited. Specific binding members for ngf
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CA2695997C (en) 2007-08-10 2016-11-22 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human nerve growth factor
WO2009054468A1 (ja) 2007-10-24 2009-04-30 Astellas Pharma Inc. アゾールカルボキサミド化合物又はその塩
PL2448970T3 (pl) 2009-05-04 2014-12-31 Abbvie Res B V Przeciwciało przeciwko czynnikowi wzrostu nerwów (NGF) ze zwiększoną stabilnością in vivo

Also Published As

Publication number Publication date
US20140155582A1 (en) 2014-06-05
DK2743348T3 (en) 2018-02-26
TW201319086A (zh) 2013-05-16
BR112014002576A2 (pt) 2021-01-12
TWI554519B (zh) 2016-10-21
ES2663968T3 (es) 2018-04-17
SI2743348T1 (en) 2018-04-30
AU2012293161A1 (en) 2014-02-06
WO2013022083A1 (ja) 2013-02-14
AR087506A1 (es) 2014-03-26
CN103748222A (zh) 2014-04-23
JPWO2013022083A1 (ja) 2015-03-05
EP2743348A1 (en) 2014-06-18
CA2841181A1 (en) 2013-02-14
NO2743348T3 (ru) 2018-06-09
EA024292B1 (ru) 2016-09-30
RS56876B1 (sr) 2018-04-30
US20150218265A1 (en) 2015-08-06
US8986952B2 (en) 2015-03-24
CN103748222B (zh) 2015-07-22
LT2743348T (lt) 2018-05-10
HRP20180155T1 (hr) 2018-03-23
CY1119914T1 (el) 2018-06-27
EP2743348A4 (en) 2015-04-29
KR101999867B1 (ko) 2019-07-12
BR112014002576B1 (pt) 2022-08-23
ZA201400741B (en) 2014-11-26
IN2014CN00614A (ru) 2015-04-03
IL230797A (en) 2017-06-29
MX351273B (es) 2017-10-06
IL230797A0 (en) 2014-03-31
PT2743348T (pt) 2018-02-23
EP2743348B1 (en) 2018-01-10
MX2014001627A (es) 2014-05-28
PL2743348T3 (pl) 2018-04-30
ME02944B (me) 2018-04-20
AU2012293161B2 (en) 2017-04-27
JP5376095B2 (ja) 2013-12-25
CA2841181C (en) 2022-01-25
HUE036079T2 (hu) 2018-06-28
KR20140047116A (ko) 2014-04-21

Similar Documents

Publication Publication Date Title
EA201490433A1 (ru) Новое антитело против ngf человека
NZ706377A (en) Il-6 antagonists and uses thereof
EA201891833A1 (ru) Комбинация для лечения амиотрофического бокового склероза или родственных болезней
PE20142041A1 (es) Anticuerpos anti-il-36r
NI201200171A (es) Anticuerpos hacia gdf8 humano
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
EA200900037A1 (ru) Моноклональные антитела против интерлейкина-6 (il-6) и их применение
NZ610734A (en) Human antibodies to the glucagon receptor
NZ629296A (en) Humanized antibodies that recognize alpha-synuclein
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PH12019501104A1 (en) Novel anti-human muc1 antibody fab fragment
NZ611468A (en) Humanized antibodies to liv-1 and use of same to treat cancer
NZ706986A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ594682A (en) Fully human antibodies specific to cadm1
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
PH12017500094A1 (en) Novel anti-human tie-2 antibody
PE20220708A1 (es) Anticuerpos anti-cd73
AR098663A1 (es) Anticuerpos multifuncionales que se unen a egfr y met
EA201492163A1 (ru) ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К TrkA, СОДЕРЖАЩИЕ АМИНОКИСЛОТНЫЕ ЗАМЕНЫ
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
ES2684173T3 (es) Anticuerpos anti-XCR1 humano
EA201391453A1 (ru) Новое антитело против рецептора il-23 человека
CY1115897T1 (el) ΒΕΛΤΙΩΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΑΝΤΙΣΩΜΑ ΑΝΤΙ-ΑΝΘΡΩΠΙΝΗΣ ΙΝΤΕΓΓΡΙΝΗΣ α9
EA201491240A1 (ru) Новое антитело против ctgf человека

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM